ADVANCES IN TARGETED THERAPIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS

Abstract

Light chain amyloidosis (AL) is a complex disorder resulting from the deposition of misfolded proteins in vital organs, requiring rapid interventions to prevent irreversible damage, especially in the cardiac and renal systems. This study aims to analyze recent scientific evidence on advances in targeted therapies for the disease, using a narrative literature review based on PubMed data from the past five years. The results indicate that the introduction of the monoclonal antibody daratumumab into the standard regimen (Dara-CyBorD) has revolutionized first-line treatment, increasing complete hematologic response rates to over 50%. For cases of relapse or refractory disease, promising options have emerged, such as elranatamab and venetoclax, the latter specifically targeting patients with the t(11;14) translocation. In addition, new research directions focus on therapies that remove existing amyloid deposits, aiming at direct recovery of affected organs. It is concluded that the management of AL amyloidosis is moving toward increasingly personalized precision medicine, where early diagnosis and the achievement of deep hematologic responses are key to transforming the prognosis into a chronic and controllable condition.